The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products
Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.
The PCN recommends Infliximab (biosimilar) for immunotherapy related colitis in line with the St Luke’s Cancer Alliance guidelines.
Prescribing will be by hospital specialists only, using Blueteq initiation forms. Infliximab (biosimilar) will be considered RED on the traffic light system
